Medications for Incontinence: What They Are, How They Work, and Their Limits

When a patient reports bladder leaks or sudden urgency, medication is often the first thing a doctor reaches for. That's not necessarily wrong — bladder medications have a legitimate role and can provide real relief for certain patients. But there's quite a bit that typically doesn't get discussed during a brief office visit: the critical limitations, the high dropout rate, the side effect tradeoffs, and the fact that these medications don't do anything to address the underlying cause of incontinence.

This guide covers the main drug classes used for incontinence — what they are, how they actually work, and an honest assessment of where they help and where they don't.

The Most Important Thing to Know First

Before getting into the specifics, there's one fact that changes everything:

Bladder medications only treat urge incontinence and overactive bladder (OAB). They do nothing for stress incontinence.

Stress incontinence — leaking when you cough, sneeze, laugh, jump, or exercise — is caused by a weakened pelvic floor and urethral sphincter. No currently approved oral medication addresses this. If you're experiencing primarily stress incontinence, medication isn't the right tool.

Urge incontinence — the sudden, intense need to urinate followed by leaking — is caused by an overactive bladder that contracts involuntarily. This is what bladder medications target.

The problem is that many people have mixed incontinence — both stress and urge components simultaneously. Medication may help the urge side, but leaves the stress side entirely unaddressed.

Class 1: Anticholinergics (Antimuscarinics)

These are the oldest and most widely prescribed medications for overactive bladder. You may have been prescribed one without knowing the category name.

How They Work

The bladder is controlled partly by the parasympathetic nervous system, which uses acetylcholine as its chemical messenger. When acetylcholine binds to muscarinic receptors (specifically M2 and M3) in the bladder wall, it triggers contraction. Anticholinergic medications block these receptors, reducing the bladder's tendency to contract involuntarily.

The result: fewer involuntary contractions, reduced urgency, and decreased leakage episodes. The bladder doesn't contract as aggressively in response to filling.

Common Anticholinergic Medications

Oxybutynin (Ditropan, Oxytrol, Gelnique)
The original and most widely known. Available as an immediate-release pill, extended-release pill, transdermal patch (Oxytrol), and topical gel (Gelnique). The immediate-release version has the highest rate of side effects. The patch and gel forms bypass first-pass liver metabolism and have somewhat better tolerability. Generic versions are inexpensive.

Tolterodine (Detrol, Detrol LA)
More bladder-selective than oxybutynin, meaning it has slightly less effect on other organs. Detrol LA (once daily) is better tolerated than twice-daily formulations. A common alternative when oxybutynin side effects are a problem.

Solifenacin (VESIcare)
Once-daily dosing. Considered more bladder-selective with a somewhat improved dry mouth profile compared to oxybutynin. Commonly prescribed for patients who need a longer-acting option.

Darifenacin (Enablex)
Highly selective for M3 receptors (the subtype most involved in bladder contraction), which theoretically reduces cognitive side effects. Once daily.

Fesoterodine (Toviaz)
Converted to the same active metabolite as tolterodine, but at adjustable doses. Once daily.

Trospium (Sanctura)
Does not cross the blood-brain barrier as readily as other anticholinergics because of its chemical structure, which may reduce cognitive side effects. Particularly relevant for older patients.

How Well Do They Work?

Clinical trials show anticholinergics typically reduce urgency incontinence episodes by around 50-70% compared to baseline.^[1] About 60-70% of patients report improvement in symptoms. This is meaningful — but it also means 30-40% of patients see little benefit, and "improvement" is not the same as resolution.

Side Effects: The Honest Version

Because muscarinic receptors aren't found only in the bladder — they're throughout the body — blocking them produces effects everywhere:

• Dry mouth — The most common side effect, affecting 30-40% of patients. Caused by reduced saliva production. Ranges from mild to severe enough to cause difficulty eating, speaking, or sleeping. A leading reason patients stop the medication.
• Constipation — Muscarinic receptors in the gut are also blocked, slowing bowel motility. Particularly problematic for older patients already prone to constipation.
• Blurred vision — From reduced ability to focus (accommodation), due to effects on the eyes.
• Urinary retention — Paradoxically, blocking bladder contractions too effectively can make it difficult to fully empty the bladder. More common in men with prostate enlargement.
• Cognitive effects — Older agents, particularly immediate-release oxybutynin, cross the blood-brain barrier and can cause confusion, memory problems, and brain fog. This is especially concerning in older adults.

The Dementia Connection

This one deserves its own paragraph. A significant 2015 study published in JAMA Internal Medicine found that cumulative use of anticholinergic medications was associated with increased risk of dementia, with stronger associations for longer durations of use.^[4] The risk was highest with older agents that cross the blood-brain barrier more readily — including oxybutynin.

This doesn't mean everyone taking these medications will develop dementia, and there is ongoing debate about causality. But it's a real consideration, particularly for long-term use in older adults, and something patients deserve to know before starting treatment.

Class 2: Beta-3 Adrenergic Agonists

These are a newer class of bladder medications, developed specifically to address the side effect problems of anticholinergics.

How They Work

Instead of blocking a receptor, beta-3 agonists activate the beta-3 adrenergic receptor in the bladder's detrusor muscle. When stimulated, these receptors cause the muscle to relax during the bladder-filling phase — increasing the amount of urine the bladder can hold before it signals urgency.

This is a fundamentally different mechanism from anticholinergics, which means different side effects. Notably: no dry mouth, no constipation, and no cognitive effects from muscarinic blockade.

Mirabegron (Myrbetriq)

FDA-approved in 2012, mirabegron was the first beta-3 agonist available in the US. Clinical trials show efficacy comparable to anticholinergics — significant reductions in urgency episodes and incontinence.^[3]

Side effects: The main concern is elevated blood pressure. Mirabegron increases blood pressure through the same adrenergic mechanism that helps the bladder. It's contraindicated in patients with severe, uncontrolled hypertension, and blood pressure should be monitored. Other side effects include nasopharyngitis (cold-like symptoms), urinary tract infection, and headache. Mirabegron also interacts with several other medications through CYP2D6 enzyme pathways, which is worth reviewing with your prescribing physician.

Vibegron (Gemtesa)

Approved in 2020, vibegron is the newer beta-3 agonist. It has a more selective mechanism and significantly fewer drug interactions than mirabegron, making it preferable for patients on complex medication regimens. Efficacy is similar, with a slightly better cardiovascular side effect profile in some patients. Still relatively new, so long-term data continues to accumulate.

Other Medications Sometimes Used

Alpha-Blockers (for Men)

Medications like tamsulosin (Flomax), alfuzosin (Uroxatral), and silodosin (Rapaflo) relax the smooth muscle in the prostate and bladder neck. They don't treat incontinence directly, but men with benign prostatic hyperplasia (BPH) often experience urgency and frequency alongside incomplete bladder emptying. Alpha-blockers improve urinary flow and reduce those symptoms. Often prescribed alongside OAB medications in men with mixed BPH/OAB presentations.

Topical Estrogen (for Menopausal Women)

Low-dose estrogen applied locally (cream, ring, or suppository) restores thickness and elasticity to urethral and vaginal tissue that thins during menopause. This can meaningfully reduce urgency and frequency. It's not classified as a "bladder medication" per se, but it addresses a hormonal root cause of urge-type symptoms in menopausal women with very low systemic absorption and a favorable safety profile. Worth discussing with your OB-GYN if menopause is a factor in your symptoms.

Why Most People Stop

Here's a fact that rarely comes up in the prescribing conversation: the majority of patients stop taking bladder medications within 6-12 months.^[2]

The reasons are predictable:

• Side effects — Dry mouth, constipation, and brain fog are difficult to tolerate indefinitely, especially when the benefit isn't dramatic
• Insufficient effect — Reducing episodes by 50-70% is real improvement, but many patients were hoping for much more and find the benefit doesn't justify continuing
• Cost — Brand-name versions like Myrbetriq and VESIcare are expensive; generic options are less costly but may be less tolerable
• Lack of follow-up — Patients are often prescribed and not followed up with, leaving problems unaddressed

Persistence with medication means symptoms return. Because these drugs manage the condition rather than treating its underlying cause, stopping them typically means the urgency comes back within days to weeks.

What Medications Cannot Do

Being clear about this is important:

• They cannot strengthen the pelvic floor. Incontinence related to weak pelvic floor muscles — stress incontinence, postpartum incontinence, post-prostatectomy incontinence — requires actual muscle strengthening. No pill achieves this.
• They cannot cure stress incontinence. If you leak with coughing, sneezing, or exercise, medications will not help.
• They don't produce lasting change. Unlike strengthening the pelvic floor through Emsella or pelvic floor PT, medications provide only temporary symptom management. There is no cumulative benefit — the drug is active in your system or it isn't.
• They cannot address the hormonal or structural causes of menopausal incontinence. In postmenopausal women, the pelvic floor tissue changes are ongoing. Bladder medications reduce urgency symptoms but don't restore tissue health or muscle function.

How to Think About Medications vs. Other Options

Medications aren't bad — they're just one tool, and the right tool for a specific situation. Here's a practical framework:

Medications may be appropriate if you:

• Have predominantly urge incontinence or OAB with no stress component
• Need relief quickly while pursuing a more durable treatment (Emsella, pelvic floor PT)
• Have mild-to-moderate symptoms with tolerable side effects
• Are not a candidate for other treatments due to health conditions

Medications are likely not the right primary approach if you:

• Have primarily stress incontinence (leaking with activity)
• Have mixed incontinence and want to address both components
• Are older and concerned about anticholinergic cognitive effects
• Want a lasting solution rather than ongoing symptom management
• Have tried medications and found the side effects or results unsatisfactory

Medication + Emsella

For patients with significant mixed incontinence, combining short-term medication with a course of Emsella can make sense: the medication reduces urgency symptoms during treatment while Emsella addresses the underlying pelvic floor weakness. Many patients are able to taper off medication once pelvic floor strength is restored. This combination approach should be discussed with your prescribing physician.

The Bottom Line

Bladder medications are real tools with real benefits — for the right patient, with the right type of incontinence, and realistic expectations. They reduce urgency episodes meaningfully for many people. But they're also genuinely limited: they only address one type of incontinence, symptoms return when you stop, side effects are significant for a large percentage of patients, and the majority of people don't stay on them long-term.

The key questions to ask your doctor before starting a bladder medication:

• Which type of incontinence do I actually have — urge, stress, or mixed?
• If I have a stress component, what will address that?
• What side effects should I realistically expect with this medication?
• Are there non-drug alternatives that would address the underlying cause?
• If I try this medication and it doesn't work or I can't tolerate it, what's next?

Incontinence is a medical condition with multiple causes — and the treatment should match the cause, not just the most convenient prescription.